Agios Appoints Catherine Owen to Board of Directors

– John Maraganore Completes Tenure on Agios Board After Nearly a Dozen Years of Service –

– Kaye Foster to Be Appointed Lead Independent Director –

CAMBRIDGE, Mass., May 25, 2023 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare diseases, today announced that Catherine Owen has been appointed to its board of directors, effective June 13, 2023. Agios also announced that, following a collaborative succession planning process, John Maraganore, Ph.D., who has served as a valuable board member and advisor to the company since 2011, will step down from the board of directors, effective immediately, and that Kaye Foster, who has served as a member of the board of directors since 2014, will assume the role of lead independent director.

“Catherine has an illustrious track record of delivering value to patients around the world through her leadership of U.S. and global market commercialization strategies and teams at well known, large pharmaceutical companies. Her expertise will be a tremendous asset to Agios as we strive to transform the lives of patients with PK deficiency, thalassemia, sickle cell disease, myelodysplastic syndromes and beyond,” said Brian Goff, chief executive officer of Agios.

“We would also like to express our gratitude to John for nearly a dozen years of dedicated service to our board. With his extensive background and experience in our industry, including his former role as founding CEO of Alnylam, a company he successfully built and grew into a global, leading RNAi company, he has been a significant contributor to our success and a trusted advisor to the management team and other board members. We wish him all the best in his current and future endeavors,” continued Mr. Goff. “We are also thrilled to have Kaye step into her role as lead independent director. She has added tremendous value to Agios over her long tenure, and we will continue to benefit from her insights and expertise.”

Ms. Owen brings to Agios nearly 30 years of experience in the industry and deep expertise in commercializing transformative medicines both in the U.S. and globally. In her current role as senior vice president and general manager, U.S. commercialization at Bristol Myers Squibb, Ms. Owen leads the company’s cardiovascular, immunology and oncology U.S. commercialization efforts, which contributed more than one-third of the company’s total revenue in 2022 exceeding $17 billion, and oversees a team of more than 2,500 employees. Prior to her current role, Ms. Owen was senior vice president, major markets, at Bristol Myers Squibb, responsible for the company’s business in the largest global markets including Europe, Japan and Canada. In this role, she also led multiple new product launches in multiple sclerosis, multiple myeloma, lung cancer, renal cancer and ulcerative colitis.